Editas Medicine said Thursday afternoon it will lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell disease and shifts focus.

In-vivo gene editing, which alters genetic material within the patient, could expand the potential of CRISPR-based gene editing, Editas said. The company said it aims to demonstrate proof of concept ...

The Cambridge, Mass.-based company on Thursday said it will now focus on in vivo Crispr-edited medicines based on its researchers recent scientific progress in multiple tissues. At the same time, it ...

In October, Editas revealed plans to change course, announcing that it would seek to license out its lead CRISPR medicine for sickle cell disease. That search did not identify a commercial partner, ...

When hiring job candidates to work on cell and gene therapies, companies look for more than just technical skills. Talent ...

Researchers expand the CRISPR genome engineering toolbox with transposase-assisted target-site integration (TATSI), a ...

How does CRISPR work, and why is editing human embryos so controversial? Explore the science, the risks, and the ethical debates surrounding Dr. He Jiankui’s gene-editing experiment.

The new company has also raised $75 million that will support the development of epigenetic editing therapies for hepatitis B ...

Research analysts at William Blair issued their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a report issued on Monday, December 9th. William Blair analyst S. Corwin ...

Cells in the immune system don't always fight; they often rest and wait for threats, like viruses or bacteria.

A research team have recently published their article, "Rationally designed pooled CRISPRi-seq uncovers an inhibitor of ...

Cells in the immune system don't always fight; they often rest and wait for threats, like viruses or bacteria. When such ...